%0 Journal Article
%T Development and applications of oncolytic Maraba virus vaccines
%A Brian D Lichty
%A Byram W Bridle
%A Caroline J Breitbach
%A Chantal G Martin
%A David F Stojdl
%A Fabrice Le Boeuf
%A Jean-Simon Diallo
%A Jeff L Hummel
%A John C Bell
%A Jonathan G Pol
%A Julia Pomoransky
%A Kyle B Stephenson
%A Matthew J Atherton
%A Yonghong Wan
%J Archive of "Oncolytic Virotherapy".
%D 2018
%R 10.2147/OV.S154494
%X Oncolytic activity of the MG1 strain of the Maraba vesiculovirus has proven efficacy in numerous preclinical cancer models, and relied not only on a direct cytotoxicity but also on the induction of both innate and adaptive antitumor immunity. To further expand tumor-specific T-cell effector and long-lasting memory compartments, we introduced the MG1 virus in a prime-boost cancer vaccine strategy. To this aim, a replication-incompetent adenoviral [Ad] vector together with the oncolytic MG1 have each been armed with a transgene expressing a same tumor antigen. Immune priming with the Ad vaccine subsequently boosted with the MG1 vaccine mounted tumor-specific responses of remarkable magnitude, which significantly prolonged survival in various murine cancer models. Based on these promising results, we validated the safety profile of the Ad:MG1 oncolytic vaccination strategy in nonhuman primates and initiated clinical investigations in cancer patients. Two clinical trials are currently under way ({"type":"clinical-trial","attrs":{"text":"NCT02285816","term_id":"NCT02285816"}}NCT02285816; {"type":"clinical-trial","attrs":{"text":"NCT02879760","term_id":"NCT02879760"}}NCT02879760). The present review will recapitulate the discoveries that led to the development of MG1 oncolytic vaccines from bench to bedside
%K Maraba MG1
%K oncolytic virus
%K tumor antigen
%K cancer vaccine
%K MAGE-A3
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6263248/